Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study
Cornerstone Pharmaceuticals
Philip A Philip; Vaibhav Sahai; Nathan Bahary; Amit Mahipal; Anup Kasi; Caio Max S Rocha Lima; Angela T Alistar; Paul E Oberstein; Talia Golan; Jean-Philippe Metges; Jill Lacy; Christos Fountzilas; Charles D Lopez; Michel Ducreux; Pascal Hammel; Mohamed Salem; David Bajor; Al B Benson; Sanjeev Luther; Timothy Pardee; Eric Van Cutsem